Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage lung cancer. The purpose of this study was to investigate the optimal dose distribution and prognostic factors for local control (LC) after SBRT for lung cancer. A total of 104 lung tumors from 100 patients who underwent SBRT using various treatment regimens were analyzed. Dose distributions were corrected to the biologically effective dose (BED). Clinical and dosimetric factors were tested for association with LC after SBRT. The median follow-up time was 23.8 months (range, 3.4–109.8 months) after SBRT. The 1- and 3-year LC rates were 95.7% and 87.7%, respectively. In univariate and multivariate analyses, pathologically confirmed squamous cell carcinoma (SQ), T2 tumor stage, and a Dmax < 125 Gy (BED10) were associated with worse LC. The LC rate was significantly lower in SQ than in non-SQ among tumors that received a Dmax < 125 Gy (BED10) (p = 0.016). However, there were no significant differences in LC rate between SQ and non-SQ among tumors receiving a Dmax ≥ 125 Gy (BED10) (p = 0.198). To conclude, SQ, T2 stage, and a Dmax < 125 Gy (BED10) were associated with poorer LC. LC may be improved by a higher Dmax of the planning target volume.
A 60-year-old woman presented with abnormal genital bleeding. Colposcopy and cystoscopy revealed black pigmented lesions in the vulva, vaginal vestibule, vaginal fornix, external urethral orifice, and urethral mucosa. The patient was diagnosed with vaginal malignant melanoma and urethral invasion. Because the melanoma was confined to the vagina and urethra, high-dose-rate brachytherapy using Ir-192 was selected. Vaginal lesions were irradiated using a vaginal applicator and the urethral lesions were irradiated by inserting a flexible catheter into the urethral catheter. The total radiation dose was 48 Gy in eight fractions. Pembrolizumab was started one month after radiotherapy. All black pigmented lesions disappeared within six months after brachytherapy. There was no sign of recurrence at 15 months after treatment. Adverse events included Grade 2 perivaginal inflammation at 6 weeks after treatment and Grade 3 vaginal stenosis at 15 months after treatment. The combination of intracavitary irradiation using a vaginal applicator and transurethral irradiation using a flexible catheter within a urethral catheter enabled delivery of an adequate tumor dose.
BACKGROUND Bleeding is a common complication of advanced gastrointestinal malignancies. Although radiotherapy is an effective hemostatic treatment, dose-fractionation remains unclear. Single-fraction 8 Gy radiotherapy has been demonstrated in palliative irradiation for conditions such as bone and liver metastases; however, its effectiveness in hemostatic radiotherapy remains uncertain. OBJECTIVE This study aims to prospectively evaluate the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. METHODS This is a prospective, multicenter, single-arm, open-label phase II trial evaluating single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. A total of 47 patients will be enrolled from 12 institutions in Japan. The primary endpoint is the hemostasis rate at 4 weeks after radiotherapy in the intention-to-treat population. Secondary endpoints include hemostasis rates at other time points, changes in hemoglobin levels, transfusion requirements, incidence of rebleeding, rebleeding-free interval, salvage treatment use, overall survival, antiemetic use, patient-reported toxicity, and health-related quality of life. RESULTS The study protocol was approved by the Hiroshima University Hospital Institutional Review Board in October 2025, and patient enrollment began in the same month. Recruitment is ongoing. CONCLUSIONS The STABLE study will provide prospective evidence regarding the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. The findings may help increase access to a less burdensome hemostatic approach for patients with bleeding gastrointestinal malignancies. CLINICALTRIAL This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; UMIN000059269).